If you have been reading about WADA and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
The Laténium is an archeology museum located in Laténa, Switzerland. Its name refers to the famous nearby site of La Tène which gave its name to the Second European Iron age. The Laténium is composed of a 2,500 m2 (27,000 ft2) park and a museum building which also harbours the archaeological section of the Heritage Offices of the State of Neuchâtel, as well as the chair of prehistory of the University of Neuchâtel. The museum and its park are built on what used to be three archaeological sites that were excavated during the construction of the A5 motorway. Theses sites date from the Upper Paleolithic, Bronze Age and Neolithic. The park features dolmens and glacial erratics, reconstitutions of prehistoric and antique devices (a La Tène house, a Gallo-Roman ship and a Celtic bridge, notably), and modern works of art. The museum displays the Bevaix boat, a 20 m (66 ft) Gallo-Roman ship found in Bevaix. Items from periods comprised between the Paleolithic to the Middle Ages are on display, including the remains of a Magdalenian hunting camp.
=== Management buyout and retro theming (1995–2001) === In 1995, the chain was bought from Unilever by senior management. During 1997 and 1998, Drew Carey served as a spokesperson for the chain, appearing in TV ads alongside the Great Root Bear; he was dismissed (with legal action ensuing) after a November 1998 episode of The Drew Carey Show featured Carey eating at a McDonald's location in China.
Two Greeks submerged and surfaced in the river Tagus near the City of Toledo several times in the presence of The Holy Roman Emperor Charles V, without getting wet and with the flame they carried in their hands still alight. In 1578, the English mathematician William Bourne recorded in his book Inventions or Devises one of the first plans for an underwater navigation vehicle. A few years later the Scottish mathematician and theologian John Napier wrote in his Secret Inventions (1596) that "These inventions besides devises of sayling under water with divers other devises and strategems for harming of the enemyes by the Grace of God and worke of expert Craftsmen I hope to perform." It is unclear whether he carried out his idea. Jerónimo de Ayanz y Beaumont (1553–1613) created detailed designs for two types of air-renovated submersible vehicles. They were equipped with oars, autonomous floating snorkels worked by inner pumps, portholes and gloves used for the crew to manipulate underwater objects. Ayanaz planned to use them for warfare, using them to approach enemy ships undetected and set up timed gunpowder charges on their hulls. The first submersible of whose construction there exists reliable information was designed and built in 1620 by Cornelis Drebbel, a Dutchman in the service of James I of England. It was propelled by means of oars.
The primary medical treatment of acromegaly is to use somatostatin analogues – octreotide (Sandostatin) or lanreotide (Somatuline). Somatostatin analogues are also sometimes used to shrink large tumors before surgery. Because octreotide inhibits gastrointestinal and pancreatic function, long-term use causes digestive problems such as loose stools, nausea, and gas in one-third of people. In addition, approximately 25 percent of people with acromegaly develop gallstones, which are usually asymptomatic. In some cases, octreotide treatment can cause diabetes because somatostatin and its analogues can inhibit the release of insulin. With an aggressive adenoma that is not able to be operated on, there may be a resistance to octreotide in which case a second-generation SSA, pasireotide, may be used for tumor control. However, insulin and glucose levels should be carefully monitored as pasireotide has been associated with hyperglycemia by reducing insulin secretion.
Sources: en.wikipedia.org
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus. Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. There are three major drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.
Mirror-image life (also called mirror life) is a hypothetical form of life using mirror-reflected molecular building blocks. The successful creation of mirror-image life had previously been the goal of some scientists as a scientific achievement and a potential tool for biomanufacturing of mirror-image molecules. In 2024, a team of 38 scientists, including two Nobel laureates and several researchers previously involved in developing mirror-image life, published a report suggesting that mirror-image life could pose catastrophic risks to health and the environment. Unlike simple mirror-image molecules, mirror-image organisms such as bacteria could reproduce and might irreversibly spread through ecosystems. Such bacteria might be able to evade many components of immune systems, causing fatal infections in humans, animals, and plants. Some scientists, bioethicists, policymakers, and civil society groups have recommended that governance be established to ensure that mirror-image life is not created, and some funders have refused to support research with the goal of creating mirror-image life. Discussions are ongoing about the risks of mirror life and appropriate governance. Certain mirror-image components of molecular machinery have been synthesized in laboratories and efforts to chemically synthesize a mirror-image ribosome have been ongoing since 2016. Although entire mirror organisms could in principle be created, some scientists estimate 10 to 30 years before the creation of mirror-image life is possible.
=== Alternative medicine === Some alternative practitioners believe EDTA acts as an antioxidant, preventing free radicals from injuring blood vessel walls, therefore reducing atherosclerosis. These ideas are unsupported by scientific studies, and seem to contradict some currently accepted principles. The U.S. FDA has not approved it for the treatment of atherosclerosis.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.